Cargando…

Iron parameters in patients with partial lipodystrophy and impact of exogenous leptin therapy

Detalles Bibliográficos
Autores principales:	Akinci, Efe Y, Boutros, Sabine, Ryan, Benjamin J, Sargin, Pinar, Akinci, Baris, Neidert, Adam H, Hench, Rita, Horowitz, Jeffrey F, Oral, Elif A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354259/ https://www.ncbi.nlm.nih.gov/pubmed/34373262 http://dx.doi.org/10.1136/bmjdrc-2021-002385

Ejemplares similares

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

Inhibition of Angiopoietin-Like 3 (ANGPTL3) Reduces Adipose Tissue Insulin Resistance in Patients With Familial Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

MON-101 The LD Lync Study: Natural History Study of Lipodystrophy Syndromes: Early Lessons from the Pilot Data
por: Jalal Eldin, Abdelwahab, et al.
Publicado: (2019)

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
por: Akinci, Baris, et al.
Publicado: (2020)

SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

Abnormal Non Esterified Fatty Acid Suppression After a Mixed Meal Test in Patients With Partial Lipodystrophy
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

2287 ECG and echo characteristics in familial partial lipodystrophy: The impact of Lamin A variants
por: Eldin, Abdelwahab J., et al.
Publicado: (2018)

Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis
por: Cook, Keziah, et al.
Publicado: (2021)

Current Diagnosis, Treatment and Clinical Challenges in the Management of Lipodystrophy Syndromes in Children and Young People
por: Özen, Samim, et al.
Publicado: (2020)

Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
por: Foss-Freitas, Maria C., et al.
Publicado: (2021)

MON-121 Pain Is a Major Driver of Quality of Life and Psychoemotional Health in Lipodystrophy Syndromes
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

SAT-622 Heterogeneity of Familial Partial Lipodystrophy Type 2 from a Genotype-Phenotype Perspective
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2020)

SAT-617 Potential Utility of the Mixed Meal Test for Differential Diagnosis of Partial Lipodystrophy from Common Type 2 Diabetes and Truncal Obesity
por: Guraya, Armaan, et al.
Publicado: (2020)

Body Composition And Bone Mineral Differences According to Lamin A (LMNA) Genotype in Familial Partial Lipodystrophy Type 2
por: de Freitas, Maria Cristina Foss, et al.
Publicado: (2021)

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin
por: Esfandiari, Nazanene H., et al.
Publicado: (2019)

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program
por: Ajluni, Nevin, et al.
Publicado: (2016)

Untangling the Heterogeneity of Acquired Generalized Lipodystrophy
por: Cavdar, Umit, et al.
Publicado: (2021)

PSUN138 Demonstration of Progressive Beta-Cell Failure in Familial Partial Lipodystrophy
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

SUN-600 Presence of LMNA p.R582H Pathogenic Variant in Homozygous State Demonstrates Gene Dosage Effect on the Severity of Fat Loss in Lipodystrophy
por: Soyaltin, Utku Erdem, et al.
Publicado: (2020)

FRI058 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Metabolic Parameters In Individuals With Generalized Lipodystrophy
por: Olenchock, Ben, et al.
Publicado: (2023)

Homozygous LMNA p.R582H pathogenic variant reveals increasing effect on the severity of fat loss in lipodystrophy
por: Soyaltin, Utku Erdem, et al.
Publicado: (2020)

SAT-574 Whole Exome Sequencing Identifies Several Variants Associated with Immune Deficiency, Inflammasomopathy and Non-Ischemic Dilated Cardiomyopathy in a Complex Case of Acquired Generalized Lipodystrophy
por: Brandao, Marjorie Azevedo Jales, et al.
Publicado: (2020)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges
por: Chiquette, Elaine, et al.
Publicado: (2017)

Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
por: Saydam, O, et al.
Publicado: (2021)

FRI069 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Weight And Associated Comorbidities In Congenital Leptin Deficiency
por: Ozsu, Elif, et al.
Publicado: (2023)

RF24 | PSUN126 A Very-Low Calorie Diet Can Reduce Insulin Resistance and Cause Remission of Diabetes Mellitus and Hypertriglyceridemia in a Patient With Familial Partial Lipodystrophy Type 2
por: De Freitas, Maria Foss, et al.
Publicado: (2022)

FRI055 LYNC-LD: Prospective Multicenter Natural History Study Of Lipodystrophy Syndromes To Determine Prevalence, Incidence And Predictors Of Diabetes And Severe Hypertriglyceridemia, And Their Complications
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023)

FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023)

Leptin in Relation to the Lipodystrophy-Associated Metabolic Syndrome
por: Mantzoros, Christos S.
Publicado: (2012)

European lipodystrophy registry: background and structure
por: von Schnurbein, Julia, et al.
Publicado: (2020)

Type 2 Diabetes With Partial Lipodystrophy of the Limbs: A new lipodystrophy phenotype
por: Strickland, Leah R., et al.
Publicado: (2013)

Long Term Effects of Leptin on Hepatic Fibrosis in Generalized Lipodystrophy
por: Lightbourne, Marissa, et al.
Publicado: (2021)

Leptin Improves Cardiac Structure and Function in Patients With Generalized Lipodystrophy
por: Nguyen, My-Le, et al.
Publicado: (2021)

Adiponectin and leptin levels in HIV-infected patients with lipodystrophy in Southern India
por: Jacob, S Mini, et al.
Publicado: (2010)

Leptin Decreases Energy Expenditure but Increases Thyroid Hormone in Patients With Lipodystrophy
por: Quaye, Emmanuel, et al.
Publicado: (2021)

A new mutation in the CAVIN1/PTRF gene in two siblings with congenital generalized lipodystrophy type 4: case reports and review of the literature
por: Mancioppi, Valentina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1qkduppc58skfim99n19tnns9j